Association of TEs and clinical characteristics at diagnosis
| Variable . | TE (n = 56) . | No TE (n = 211) . | P value . |
|---|---|---|---|
| Demographics | |||
| Age at diagnosis, median (IQR), y | 42 (26.3-58) | 46 (27-62) | .5353 |
| Sex, n (%) | .0964 | ||
| Male | 30 (53.6) | 86 (40.8) | |
| Female | 26 (46.4) | 125 (59.2) | |
| Laboratory markers, median (IQR) | |||
| Hb (g/dL) | 9.5 (8.1-11.2) | 9.2 (8.1-10.7) | .8396 |
| ANC (×109/L) | 2.4 (1.2-3.9) | 1.4 (0.8-2.5) | .0212 |
| Platelets (×109/L) | 85 (28-137.5) | 37 (18-93) | .0064 |
| Absolute reticulocyte count (×103/μL) | 106 (61-184) | 77.5 (33.8-142) | .0392 |
| D-dimer (mg/L) | 1335 (337.5-3023) | 360 (237-820) | .0004 |
| LDH (U/L) | 603 (362-939) | 318 (311-902) | .0070 |
| AST (U/L) | 37 (18.5-61.5) | 25 (18-42.3) | .1701 |
| ALT (U/L) | 24 (17.5-56) | 20.5 (14-31.8) | .0606 |
| Creatinine (mg/dL) | 0.8 (0.66-1.07) | 0.8 (0.69-1.0) | .7700 |
| Albumin (g/dL) | 4 (3.8-4.5) | 4.3 (4.1-4.7) | .0030 |
| C-reactive protein (mg/dL) | 7.65 (2.15-19.45) | 0.7 (0.2-3) | .0459 |
| Presence of CHIP, n (%)∗ | 8 of 35 (23%) | 27 of 151 (19%) | .4798 |
| Disease characteristics | |||
| Prior AA, n (%) | 31 (55.4) | 161 (76.3) | .5505 |
| AA to PNH, time in mo, median (IQR) | 23.4 (1.5-126.4) | 36.9 (3.7-85.2) | .1385 |
| PIGA mutant, n (%) | 23 (67.7) | 124 (61.4) | .5684 |
| PIGA VAF, % (IQR) | 35.4 (14.6-47.4) | 11.6 (5.8-36.2) | .0172∗ |
| Granulocyte clone size, median (IQR) | 71.3 (42.7-92.2) | 12.8 (0.6-70.2) | <.0001 |
| RBC clone size, median (IQR) | 17.3 (5.9-49.3) | 1.8 (0.2-19.6) | <.0001 |
| Type II–dominant RBC clone, n (%) | 13 (39.4) | 13 (15.1) | .0064∗ |
| Type III–dominant RBC clone, n (%) | 20 (60.6) | 73 (84.9) |
| Variable . | TE (n = 56) . | No TE (n = 211) . | P value . |
|---|---|---|---|
| Demographics | |||
| Age at diagnosis, median (IQR), y | 42 (26.3-58) | 46 (27-62) | .5353 |
| Sex, n (%) | .0964 | ||
| Male | 30 (53.6) | 86 (40.8) | |
| Female | 26 (46.4) | 125 (59.2) | |
| Laboratory markers, median (IQR) | |||
| Hb (g/dL) | 9.5 (8.1-11.2) | 9.2 (8.1-10.7) | .8396 |
| ANC (×109/L) | 2.4 (1.2-3.9) | 1.4 (0.8-2.5) | .0212 |
| Platelets (×109/L) | 85 (28-137.5) | 37 (18-93) | .0064 |
| Absolute reticulocyte count (×103/μL) | 106 (61-184) | 77.5 (33.8-142) | .0392 |
| D-dimer (mg/L) | 1335 (337.5-3023) | 360 (237-820) | .0004 |
| LDH (U/L) | 603 (362-939) | 318 (311-902) | .0070 |
| AST (U/L) | 37 (18.5-61.5) | 25 (18-42.3) | .1701 |
| ALT (U/L) | 24 (17.5-56) | 20.5 (14-31.8) | .0606 |
| Creatinine (mg/dL) | 0.8 (0.66-1.07) | 0.8 (0.69-1.0) | .7700 |
| Albumin (g/dL) | 4 (3.8-4.5) | 4.3 (4.1-4.7) | .0030 |
| C-reactive protein (mg/dL) | 7.65 (2.15-19.45) | 0.7 (0.2-3) | .0459 |
| Presence of CHIP, n (%)∗ | 8 of 35 (23%) | 27 of 151 (19%) | .4798 |
| Disease characteristics | |||
| Prior AA, n (%) | 31 (55.4) | 161 (76.3) | .5505 |
| AA to PNH, time in mo, median (IQR) | 23.4 (1.5-126.4) | 36.9 (3.7-85.2) | .1385 |
| PIGA mutant, n (%) | 23 (67.7) | 124 (61.4) | .5684 |
| PIGA VAF, % (IQR) | 35.4 (14.6-47.4) | 11.6 (5.8-36.2) | .0172∗ |
| Granulocyte clone size, median (IQR) | 71.3 (42.7-92.2) | 12.8 (0.6-70.2) | <.0001 |
| RBC clone size, median (IQR) | 17.3 (5.9-49.3) | 1.8 (0.2-19.6) | <.0001 |
| Type II–dominant RBC clone, n (%) | 13 (39.4) | 13 (15.1) | .0064∗ |
| Type III–dominant RBC clone, n (%) | 20 (60.6) | 73 (84.9) |
ALT, alanine aminotransferase; CHIP, clonal hematopoiesis of indeterminate potential; Hb, hemoglobin.
Bold values indicate statistical significance.
Missing data (PIGA molecular information available in 91 patients, and PNH RBC clone type available in 100 patients; myeloid NGS available for 186 patients).